A Multi-centre, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Children in Canada (CATCO-Kids) [Funder: Montreal Children's Hospital Foundation]
- Funded by Other Funders (Canada)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AFunder
Other Funders (Canada)Principal Investigator
Papenburg, Jesse, Fontela PatriciaResearch Location
CanadaLead Research Institution
McGill UniversityResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Prophylactic use of treatmentsSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
Randomized Controlled TrialBroad Policy Alignment
PendingAge Group
Children (1 year to 12 years)Vulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
Can anti-malaria drugs help children with COVID-19? CATCO is a Canada-wide study that is testing the efficacy of anti-malaria drug hydroxychloroquine to treat adults hospitalized with COVID-19. Now, pediatric infectious disease specialist Dr. Jesse Papenburg and pediatric critical care expert Dr. Patricia Fontela are performing a similar study on children to determine whether the drug can reduce the severity of the COVID-19 infection, and lead to faster recovery and shorter hospital stays. This study will be the first randomized trial in children with COVID-19, and has the potential to save young lives.